Scoop has an Ethical Paywall
GMO cancer treatment gets EPA go-ahead
Monday 19 February 2018
GMO cancer treatment gets EPA go-ahead
The Environmental Protection Authority has
approved a potentially life-saving treatment for
melanoma.
“Telomelysin, a genetically modified
virus, will be used as part of a clinical trial of patients
with advanced and inoperable melanoma,” says Dr Fiona
Thomson-Carter, EPA’s General Manager of Hazardous
Substances and New Organisms.
“It is derived from a common human virus, that nearly all people are immune to from around the age of two.
“Once directly injected into the tumour, it replicates in cancer cells, targeting them for destruction,” says Dr Thomson-Carter.
The approval, under the Hazardous Substances and New Organisms Act, has been granted to applicant Oncolys BioPharma Incorporated, which will use the virus in clinical trials to explore its effectiveness and any side-effects.
“In granting the approval, the EPA has set strict controls that will protect people and the environment to enable the clinical trial to go ahead,” says Dr Thomson-Carter.
Oncolys BioPharma Inc has a five-year timeframe in which to begin the trial.
You can read more about the decision on the EPA website.
ends
John Mazenier: Gaffer Tape And Glue Delivering New Zealand’s Mission Critical Services
Earthquake Commission: Ivan Skinner Award Winner Inspired By Real-life Earthquake Experience
Reserve Bank: Consultation Opens On A Digital Currency For New Zealand
NIWA: Ship Anchors May Cause Extensive And Long-lasting Damage To The Seafloor, According To New Research
New Zealand Customs Service: A Step Forward For Simpler Trade Between New Zealand And Singapore
Horizon Research: 68% Say Make Banks Offer Fraud Protection
